[1] A. L. Phelan, R. Katz, and L. O. Gostin, “The novel coronavirus originating in Wuhan, China: challenges for global health governance,” Jama, vol. 323, no. 8, pp. 709–710, 2020.
[2] X. Li, M. Geng, Y. Peng, L. Meng, and S. Lu, “Molecular immune pathogenesis and diagnosis of COVID-19,” J. Pharm. Anal., vol. 10, no. 2, pp. 102–108, 2020.
[3] R. M. Al-Ani, “Smell and Taste Abnormalities due to COVID-19,” Al-Anbar Med. J., vol. 16, no. 1, pp. 1–2, 2020.
[4] H. Ghazzay, R. M. Al-Ani, M. A. Khalil, and A. F. Hammad, “Socio-clinical characteristics of COVID-19 disease in Anbar Governorate, Iraq,” J. Emerg. Med. Trauma Acute Care, vol. 2021, no. 1, p. 8, 2021.
[5] C. E. M. Griffiths, J. Barker, T. O. Bleiker, R. Chalmers, and D. Creamer, Rook’s textbook of dermatology, 4 volume set, vol. 1. John Wiley & Sons, 2016.
[6] I. Hamming, W. Timens, and M. L. Bulthuis, “Lely. AT, Navis, GJ, and van Goor, H.(2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis,” J Pathol, vol. 203, no. 2, pp. 631–637.
[7] C. Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” Lancet, vol. 395, no. 10223, pp. 497–506, 2020.
[8] V. De Giorgi et al., “Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy,” J. Am. Acad. Dermatol., vol. 83, no. 2, pp. 674–675, 2020.
[9] O. Askin, R. N. Altunkalem, D. D. Altinisik, T. K. Uzuncakmak, U. Tursen, and Z. Kutlubay, “Cutaneous manifestations in hospitalized patients diagnosed as COVID‐19,” Dermatol. Ther., vol. 33, no. 6, p. e13896, 2020.
[10] S. A. Bdaiwi and R. H. Abdul-saheb, “Mucocutaneous Manifestations of COVID-19 among Iraqi Patients in Al Diwaniyah Province , Iraq : Case Series Study,” vol. 2, no. 239, pp. 239–244, 2022.
[11] R. Fölster‐Holst and H. W. Kreth, “Viral exanthems in childhood. Part 3: Parainfectious exanthems and those associated with virus‐drug interactions,” JDDG J. der Dtsch. Dermatologischen Gesellschaft, vol. 7, no. 6, pp. 506–510, 2009.
[12] S. A. Castillo, A. K. Pham, and J. G. Dinulos, “Cutaneous manifestations of systemic viral diseases in neonates: an update,” Curr. Opin. Pediatr., vol. 29, no. 2, pp. 240–248, 2017.
[13] S. Recalcati, “Cutaneous manifestations in COVID-19: a first perspective [published online March 26, 2020],” J Eur Acad Dermatol Venereol. doi, vol. 10.
[14] D. Turkmen, N. Altunisik, S. Sener, and C. Colak, “Evaluation of the effects of COVID‐19 pandemic on hair diseases through a web‐based questionnaire,” Dermatol. Ther., vol. 33, no. 6, p. e13923, 2020.
[15] A. Goren et al., “A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain-A potential clue to the role of androgens in COVID-19 severity.,” 2020.
[16] G. J. Nuovo, D. Suster, E. Tili, H. Awad, and C. Magro, “A Standardization Protocol for the In Situ Detection of SARS-CoV2 RNA and Proteins,” Appl. Immunohistochem. Mol. Morphol., vol. 30, no. 2, pp. 83–90, 2022.
[17] T. P. Habif, Clinical dermatology E-book. Elsevier Health Sciences, 2015.
[18] Z. Zhou et al., “Heightened innate immune responses in the respiratory tract of COVID-19 patients,” Cell Host Microbe, vol. 27, no. 6, pp. 883–890, 2020.
[19] G. Kaya, A. Kaya, and J.-H. Saurat, “Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: review of the literature,” Dermatopathology, vol. 7, no. 1, pp. 3–16, 2020.
[20] P. Suchonwanit, K. Leerunyakul, and C. Kositkuljorn, “Cutaneous manifestations in COVID-19: lessons learned from current evidence,” J. Am. Acad. Dermatol., vol. 83, no. 1, pp. e57–e60, 2020.
[21] C.-Y. Chu, “Drug eruptions: Great imitators,” Clin. Dermatol., vol. 38, no. 2, pp. 193–207, 2020.
[22] C. Galván Casas et al., “Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases,” Br. J. Dermatol., vol. 183, no. 1, pp. 71–77, 2020.
[23] U. Wollina, A. S. Karadağ, C. Rowland‐Payne, A. Chiriac, and T. Lotti, “Cutaneous signs in COVID‐19 patients: a review,” Dermatol. Ther., vol. 33, no. 5, p. e13549, 2020.
[24] J. M. Carrascosa, V. Morillas, I. Bielsa, and M. Munera-Campos, “Cutaneous manifestations in the context of SARS-CoV-2 infection (COVID-19),” Actas Dermo-Sifiliográficas (English Ed., vol. 111, no. 9, pp. 734–742, 2020.
[25] R. Gianotti et al., “Cutaneous clinico-pathological findings in three COVID-19-positive patients observed in the metropolitan area of Milan, Italy,” 2020.
[26] T. King, B. Hewitt, B. Crammond, G. Sutherland, H. Maheen, and A. Kavanagh, “Reordering gender systems: can COVID-19 lead to improved gender equality and health?,” Lancet, vol. 396, no. 10244, pp. 80–81, 2020.
[27] O. Wu, N. Bayoumi, M. A. Vickers, and P. Clark, “ABO (H) blood groups and vascular disease: a systematic review and meta‐analysis,” J. Thromb. Haemost., vol. 6, no. 1, pp. 62–69, 2008.
[28] G. Paré et al., “Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women,” PLoS Genet., vol. 4, no. 7, p. e1000118, 2008.
[29] J. G. Ray, M. J. Schull, M. J. Vermeulen, and A. L. Park, “Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: a population-based cohort study,” Ann. Intern. Med., vol. 174, no. 3, pp. 308–315, 2021.
[30] J. Zhao et al., “Relationship between the ABO blood group and the coronavirus disease 2019 (COVID-19) susceptibility,” Clin. Infect. Dis., vol. 73, no. 2, pp. 328–331, 2021.
[31] D. McGonagle, J. S. O’Donnell, K. Sharif, P. Emery, and C. Bridgewood, “Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia,” Lancet Rheumatol., vol. 2, no. 7, pp. e437–e445, 2020.